Profile: Celgene Corp (CELG.O)
26 May 2017
Celgene Corporation, incorporated on April 17, 1986, is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier.
REVLIMID is an oral immunomodulatory drug approved in the United States and a range of international markets. REVLIMID is in various Phase III trials covering a range of hematological malignancies that include multiple myeloma, lymphomas and myelodysplastic syndromes (MDS). POMALYST/IMNOVID is administered orally and modulates the immune system and other biologically important targets. POMALYST/IMNOVID is approved for various uses, including multiple myeloma, and relapsed and refractory multiple myeloma. OTEZLA is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. OTEZLA is approved for various uses, including psoriatic arthritis and psoriasis. OTEZLA is also being studied in clinical trials in ankylosing spondylitis, Behcet's disease, atopic dermatitis and ulcerative colitis.
ABRAXANE is a solvent-free chemotherapy product, which was developed using the Company's nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. ABRAXANE is approved for various uses, including breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer and gastric cancer. VIDAZA is a pyrimidine nucleoside analog that has been shown to reverse the effects of deoxyribonucleic acid (DNA) hypermethylation and promote subsequent gene re-expression. VIDAZA is a recommended treatment for patients with intermediate-2 and high-risk MDS. VIDAZA is approved in the United States and international markets for various uses, including MDS, chronic myelomonocytic leukemia and acute myeloid leukemia (AML). THALOMID, sold as THALOMID or Thalidomide Celgene, outside of the United States, is administered orally for various uses, including multiple myeloma and erythema nodosum leprosum. ISTODAX is indicated for the treatment of cutaneous T-cell lymphoma and peripheral T-cell lymphoma.
The Company has submitted a new drug application (NDA) for AG-221 (enasidenib) for the treatment of patients with relapsed or refractory AML with isocitrate dehydrogenase-2 (IDH2) mutation. In hematology, Phase III trials are underway for CC-486 and luspatercept in MDS; for CC-486 and enasidenib in AML, and for luspatercept in beta-thalassemia. In the inflammation and immunology therapeutic area, the Company is conducting Phase III trials for ozanimod in relapsing multiple sclerosis (RMS) and ulcerative colitis (UC) and for GED-0301 (mongersen) in Crohn's disease. The Company is also evaluating enasidenib in combination with VIDAZA in newly diagnosed AML with IDH2 mutations.
The Company competes with AbbVie Inc., Amgen, AstraZeneca PLC, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Merck, Novartis AG, Roche, Sanofi, Takeda, Biogen, Eli Lilly, Pfizer and UCB S.A.
86 Morris Ave
SUMMIT NJ 07901-3915
Company Web Links
- Celgene MS drug clears key trial, but disability data falls short
- UPDATE 2-Celgene MS drug clears key trial, but disability data falls short
- Celgene's multiple sclerosis drug succeeds in late-stage trial
- BRIEF-Celgene announces positive results from radiance
- Celgene leukemia drug extends survival in early stage trial